Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
|
This article is part of Pulmonology Advisor‘s coverage of the American Academy of Allergy, Asthma & Immunology, taking place in Orlando, Florida. Our staff will report on medical research related to asthma and other respiratory conditions, conducted by experts in the field. Check back regularly for more news from AAAAI/WAO 2018. |
ORLANDO — A pooled analysis shows how intravenous reslizumab, a humanized anti-interleukin-5 monoclonal antibody, provides clinical benefits to patients aged 12 to 75 years with poorly managed asthma and blood eosinophils ≥400 cells/mL (110 mL [95% CI, 67-150 mL]).
These patients showed improvement in forced expiratory volume in the first second of expiration (FEV1) at 52 weeks. This increase may indicate a reduction in air trapping and recruitment of small peripheral airways. The research was presented at the 2018 joint congress of the American Academy of Allergy, Asthma & Immunology and the World Allergy Organization, held March 2-5, 2018, in Orlando, Florida.
The study was a joint effort by researchers at the Allergy and Asthma Associates of Southern California, Mission Viejo, California, and Teva Branded Pharmaceutical Products R&D Inc, Malvern, Pennsylvania. They pooled data from 2 separate placebo-controlled trials with the outcomes measuring both forced vital capacity (FVC) and forced expiratory flow (FEF) 25%-75%.
The mean difference in the reslizumab treatment vs the placebo over 15 and 52 weeks in FVC was 108 mL (95% CI, 55-161; P =.0008) and 104 mL (95% CI, 51-158; P =.0012), respectively.
Patients saw improvement at the first 4-week assessment with just 1 dose of reslizumab. One treatment offered FVC improvement of 128 mL (95% CI: 69-186; P <.0001) in comparison with the placebo group.
Improvement in FVC following reslizumab administration was significant at 128 mL (95% CI, 69-186; P <.0001) compared with placebo. Mean treatment difference for reslizumab relative to placebo over 16 and 52 weeks in FEF 25%-75% was: 102 mL (95% CI, 42-161; P =.008) and 99 mL (95% CI, 39-158; P =.0012), respectively. The first assessment after 4 weeks showed a treatment difference of 102 mL (95% CI, 34-171; P =.0034).
The research demonstrates that reslizumab may improve FVC and FEF 20%-75% in patients with inadequately controlled asthma and blood eosinophilia.
|
Visit Pulmonology Advisor‘s conference section for continuous coverage from AAAAI/WAO 2018 |
Reference
Carr WW, McDonald M, Meizlik P. Reslizumab improves FVC and FEF 25%-75% in severe eosinophilic asthma: results from a pooled analysis. Poster presentation at: 2018 AAAAI/WAO Joint Congress; March 2-5, 2018; Orlando, FL. Abstract 613.
